VSTM
Verastem, Inc.
Price Chart
Latest Quote
$5.77
+0.04 (+0.70%)
Current Price
| Previous Close | $5.73 |
| Open | $5.75 |
| Day High | $5.80 |
| Day Low | $5.50 |
| Volume | 1,977,156 |
Stock Information
| Shares Outstanding | 87.87M |
| Total Debt | $85.47M |
| Cash Equivalents | $181.68M |
| Revenue | $49.59M |
| Net Income | $-193.96M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $529.88M |
| EPS (TTM) | $-2.52 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $433.68M |
| Sales | $49.59M |
| Income | $-193.96M |
| Book/sh | $0.93 |
| Cash/sh | $2.07 |
| Employees | 102 |
Financial Ratios
| Quick Ratio | 2.87 |
| Current Ratio | 3.04 |
| Debt/Eq | 104.52 |
Returns & Margins
| ROA | -59.40% |
| ROE | -786.15% |
| Gross Margin | 85.13% |
| Operating Margin | -240.46% |
Ownership
| Insider Ownership | 0.93% |
| Institutional Ownership | 98.32% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -5.20 |
| P/S | 10.69 |
| P/B | 6.48 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $15.00 |
Technical Indicators
| SMA20 | $4.68 |
| SMA50 | $4.45 |
| SMA200 | $6.59 |
| RSI | 92.45 |
| ATR | 0.4386 |
| Shares Float | 70.38M |
| Short Float | 27.64% |
| Short Ratio | 8.14 |
| Volatility | 0.29 |
| Rel Volume | 1.07 |
Performance History
| Week | +9.04% |
| Month | +50.37% |
| Quarter | -4.89% |
| 6 Months | -11.19% |
| YTD | -16.60% |
| Year | +14.86% |
| 3 Years | -33.37% |
| 5 Years | -86.71% |
| 10 Years | -62.22% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $6.03 | 3,560,900 |
| 2026-07-16 | $5.77 | 1,985,600 |
| 2026-07-15 | $5.73 | 2,083,400 |
| 2026-07-14 | $5.57 | 3,004,400 |
| 2026-07-13 | $5.37 | 2,417,100 |
| 2026-07-10 | $5.53 | 2,989,300 |
| 2026-07-09 | $5.40 | 5,131,400 |
| 2026-07-08 | $5.08 | 4,355,000 |
| 2026-07-07 | $4.85 | 2,851,800 |
| 2026-07-06 | $4.46 | 1,811,500 |
| 2026-07-02 | $4.50 | 2,967,600 |
| 2026-07-01 | $4.10 | 2,186,500 |
| 2026-06-30 | $3.82 | 3,445,500 |
| 2026-06-29 | $3.82 | 2,684,200 |
| 2026-06-26 | $3.78 | 8,027,800 |
| 2026-06-25 | $3.45 | 4,598,200 |
| 2026-06-24 | $3.85 | 2,975,400 |
| 2026-06-23 | $4.21 | 2,575,800 |
| 2026-06-22 | $4.25 | 1,965,000 |
| 2026-06-18 | $4.12 | 4,765,700 |
About Verastem, Inc.
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS, which in Phase 1/2 trial entitled RAMP 203; VS-7375, and VS-7375-101 is a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers; and AVMAPKI, FAKZYNJA, CO-PACK, is an avutometinib capsules, and defactinib tablets. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
đ° Latest News
RBC Capital Reaffirms Outperform Rating For Verastem (VSTM)
Insider Monkey âĸ 2026-07-15T15:43:12Z
Verastem (VSTM) Surges 6.3%: Is This an Indication of Further Gains?
Zacks âĸ 2026-07-10T09:45:00Z
Hereâs What RBC Capital Has to Say About Verastem (VSTM)
Insider Monkey âĸ 2026-07-03T13:13:36Z
Verastem (VSTM) Shares Encouraging Results from VS-7375 Phase 1/2 Trial
Insider Monkey âĸ 2026-06-30T16:34:54Z
Is Verastem, Inc. (VSTM)âs KRAS-Targeted Combination Therapy a Breakthrough for Pancreatic Cancer?
Insider Monkey âĸ 2026-06-25T12:42:27Z
Verastem Says VS-7375 Trial Data Shows Anti-Tumor Activity in Advanced Solid Tumors
MT Newswires âĸ 2026-06-23T20:44:06ZVSTM Stock Climbs After-Hours As FDA Grants Fast Track To Lung Cancer Drug â Retail Eyes The Next Keytruda
Stocktwits âĸ 2026-06-04T00:10:41Z
Verastem (VSTM) Loses 34.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks âĸ 2026-05-18T13:35:03Z
Verastem, Inc. (NASDAQ:VSTM) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Simply Wall St. âĸ 2026-05-11T13:02:34Z
Verastem Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-09T07:10:47Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $5,298,000 | $0 | $0 | $0 |
| Cost Of Revenue | $5,298,000 | $0 | $0 | $0 |
| Total Revenue | $30,914,000 | $10,000,000 | $0 | $2,596,000 |
| Operating Revenue | $30,914,000 | $10,000,000 | $0 | $2,596,000 |
| Expenses | ||||
| Interest Expense | $1,138,000 | $4,562,000 | $4,139,000 | $2,137,000 |
| Total Expenses | $201,043,000 | $124,956,000 | $92,084,000 | $75,533,000 |
| Other Income Expense | $-42,272,000 | $-15,083,000 | $2,642,000 | $47,000 |
| Other Non Operating Income Expenses | $-12,954,000 | $4,066,000 | $2,642,000 | $47,000 |
| Net Non Operating Interest Income Expense | $2,930,000 | $-413,000 | $2,075,000 | $-922,000 |
| Interest Expense Non Operating | $1,138,000 | $4,562,000 | $4,139,000 | $2,137,000 |
| Operating Expense | $195,745,000 | $124,956,000 | $92,084,000 | $75,533,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-209,471,000 | $-130,637,000 | $-87,367,000 | $-73,812,000 |
| Net Interest Income | $2,930,000 | $-413,000 | $2,075,000 | $-922,000 |
| Interest Income | $4,068,000 | $4,149,000 | $6,214,000 | $1,215,000 |
| Normalized Income | $-180,153,000 | $-115,509,290 | $-87,367,000 | $-73,812,000 |
| Net Income From Continuing And Discontinued Operation | $-209,471,000 | $-130,637,000 | $-87,367,000 | $-73,812,000 |
| Total Operating Income As Reported | $-170,129,000 | $-114,956,000 | $-92,084,000 | $-72,937,000 |
| Net Income Common Stockholders | $-209,471,000 | $-130,637,000 | $-87,367,000 | $-73,812,000 |
| Net Income | $-209,471,000 | $-130,637,000 | $-87,367,000 | $-73,812,000 |
| Net Income Including Noncontrolling Interests | $-209,471,000 | $-130,637,000 | $-87,367,000 | $-73,812,000 |
| Net Income Continuous Operations | $-209,471,000 | $-130,637,000 | $-87,367,000 | $-73,812,000 |
| Pretax Income | $-209,471,000 | $-130,452,000 | $-87,367,000 | $-73,812,000 |
| Special Income Charges | $-1,826,000 | $0 | $0 | $0 |
| Interest Income Non Operating | $4,068,000 | $4,149,000 | $6,214,000 | $1,215,000 |
| Operating Income | $-170,129,000 | $-114,956,000 | $-92,084,000 | $-72,937,000 |
| Gross Profit | $25,616,000 | $10,000,000 | $0 | $2,596,000 |
| Per Share | ||||
| Diluted EPS | $-3.02 | $-3.66 | $-3.96 | $-4.57 |
| Basic EPS | $-3.02 | $-3.66 | $-3.96 | $-4.57 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $-4,021,290 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-178,287,000 | $-106,715,000 | $-83,166,000 | $-71,557,000 |
| Total Unusual Items | $-29,318,000 | $-19,149,000 | $0 | $0 |
| Total Unusual Items Excluding Goodwill | $-29,318,000 | $-19,149,000 | $0 | $0 |
| Reconciled Depreciation | $728,000 | $26,000 | $62,000 | $118,000 |
| EBITDA (Bullshit earnings) | $-207,605,000 | $-125,864,000 | $-83,166,000 | $-71,557,000 |
| EBIT | $-208,333,000 | $-125,890,000 | $-83,228,000 | $-71,675,000 |
| Diluted Average Shares | $69,309,000 | $35,713,000 | $22,054,000 | $16,138,000 |
| Basic Average Shares | $69,309,000 | $35,713,000 | $22,054,000 | $16,138,000 |
| Diluted NI Availto Com Stockholders | $-209,471,000 | $-130,637,000 | $-87,367,000 | $-73,812,000 |
| Tax Provision | $0 | $185,000 | $0 | $0 |
| Other Special Charges | $1,826,000 | - | - | - |
| Gain On Sale Of Security | $-27,492,000 | $-19,149,000 | - | - |
| Research And Development | $114,599,000 | $81,334,000 | $61,356,000 | $50,558,000 |
| Selling General And Administration | $81,146,000 | $43,622,000 | $30,728,000 | $24,975,000 |
Fetched: 2026-07-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $40,771,000 | $-28,893,000 | $57,374,000 | $47,391,000 |
| Total Assets | $246,442,000 | $101,538,000 | $149,718,000 | $95,050,000 |
| Total Non Current Assets | $23,029,000 | $6,577,000 | $6,036,000 | $2,180,000 |
| Other Non Current Assets | $6,112,000 | $5,140,000 | $4,828,000 | $299,000 |
| Goodwill And Other Intangible Assets | $16,426,000 | $0 | - | - |
| Other Intangible Assets | $16,426,000 | - | - | - |
| Current Assets | $223,413,000 | $94,961,000 | $143,682,000 | $92,870,000 |
| Other Current Assets | $7,577,000 | $5,943,000 | $6,553,000 | $4,945,000 |
| Inventory | $1,833,000 | $0 | - | - |
| Receivables | $200,000 | $200,000 | $0 | $31,000 |
| Other Receivables | $200,000 | $200,000 | - | - |
| Cash Cash Equivalents And Short Term Investments | $213,803,000 | $88,818,000 | $137,129,000 | $87,894,000 |
| Cash And Cash Equivalents | $204,990,000 | $88,818,000 | $77,909,000 | $74,933,000 |
| Accounts Receivable | - | $200,000 | $0 | $31,000 |
| Prepaid Assets | - | - | - | $4,945,000 |
| Debt | ||||
| Total Debt | $87,169,000 | $42,254,000 | $41,557,000 | $27,065,000 |
| Long Term Debt And Capital Lease Obligation | $81,330,000 | $41,259,000 | $40,616,000 | $25,996,000 |
| Long Term Debt | $81,330,000 | $40,724,000 | $40,086,000 | $24,526,000 |
| Current Debt And Capital Lease Obligation | $5,839,000 | $995,000 | $941,000 | $1,069,000 |
| Current Debt | $5,304,000 | - | - | $275,000 |
| Other Current Borrowings | $5,304,000 | - | - | $275,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $189,245,000 | $130,431,000 | $92,344,000 | $47,659,000 |
| Total Non Current Liabilities Net Minority Interest | $116,977,000 | $99,458,000 | $65,964,000 | $25,996,000 |
| Derivative Product Liabilities | $35,647,000 | $58,199,000 | $0 | - |
| Current Liabilities | $72,268,000 | $30,973,000 | $26,380,000 | $21,663,000 |
| Payables And Accrued Expenses | $55,569,000 | $23,733,000 | $20,316,000 | $16,040,000 |
| Interest Payable | $0 | $316,000 | $316,000 | $192,000 |
| Payables | $12,448,000 | $4,026,000 | $7,184,000 | $4,901,000 |
| Accounts Payable | $12,448,000 | $4,026,000 | $7,184,000 | $4,901,000 |
| Current Deferred Liabilities | - | $0 | $327,000 | $710,000 |
| Equity | ||||
| Common Stock Equity | $57,197,000 | $-28,893,000 | $57,374,000 | $47,391,000 |
| Total Equity Gross Minority Interest | $57,197,000 | $-28,893,000 | $57,374,000 | $47,391,000 |
| Stockholders Equity | $57,197,000 | $-28,893,000 | $57,374,000 | $47,391,000 |
| Gains Losses Not Affecting Retained Earnings | $5,229,000 | $0 | $13,000 | $0 |
| Other Equity Adjustments | $5,229,000 | - | $13,000 | - |
| Retained Earnings | $-1,164,998,000 | $-955,527,000 | $-824,890,000 | $-737,523,000 |
| Preferred Securities Outside Stock Equity | $0 | $0 | $25,348,000 | $0 |
| Other | ||||
| Ordinary Shares Number | $77,739,712 | $44,784,350 | $25,281,150 | $16,711,749 |
| Share Issued | $77,739,712 | $44,784,350 | $25,281,150 | $16,711,749 |
| Tangible Book Value | $40,771,000 | $-28,893,000 | $57,374,000 | $47,391,000 |
| Invested Capital | $143,831,000 | $11,831,000 | $97,460,000 | $72,192,000 |
| Working Capital | $151,145,000 | $63,988,000 | $117,302,000 | $71,207,000 |
| Capital Lease Obligations | $535,000 | $1,530,000 | $1,471,000 | $2,264,000 |
| Total Capitalization | $138,527,000 | $11,831,000 | $97,460,000 | $71,917,000 |
| Additional Paid In Capital | $1,216,958,000 | $926,630,000 | $882,248,000 | $784,912,000 |
| Capital Stock | $8,000 | $4,000 | $3,000 | $2,000 |
| Common Stock | $8,000 | $4,000 | $3,000 | $2,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $0 | $535,000 | $530,000 | $1,470,000 |
| Current Capital Lease Obligation | $535,000 | $995,000 | $941,000 | $794,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $10,860,000 | $6,245,000 | $4,796,000 | $3,844,000 |
| Current Accrued Expenses | $43,121,000 | $19,707,000 | $13,132,000 | $11,139,000 |
| Net PPE | $491,000 | $1,437,000 | $1,208,000 | $1,881,000 |
| Accumulated Depreciation | $-1,622,000 | $-1,618,000 | $-1,592,000 | $-1,530,000 |
| Gross PPE | $2,113,000 | $3,055,000 | $2,800,000 | $3,411,000 |
| Leases | $146,000 | $146,000 | $146,000 | $146,000 |
| Other Properties | $491,000 | $1,405,000 | $1,178,000 | $1,789,000 |
| Machinery Furniture Equipment | $1,476,000 | $1,504,000 | $1,476,000 | $1,476,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $36,000 | $0 | - | - |
| Work In Process | $1,797,000 | $0 | - | - |
| Raw Materials | $0 | $0 | - | - |
| Other Short Term Investments | $8,813,000 | $0 | $59,220,000 | $12,961,000 |
| Investments And Advances | - | - | - | - |
Fetched: 2026-07-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-147,133,000 | $-104,799,000 | $-86,460,000 | $-63,673,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-137,509,000 | $-104,771,000 | $-86,460,000 | $-63,673,000 |
| Cash Flow From Continuing Operating Activities | $-137,509,000 | $-104,771,000 | $-86,460,000 | $-63,673,000 |
| Operating Gains Losses | $29,318,000 | $19,149,000 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-9,624,000 | $-28,000 | - | - |
| Investing Cash Flow | $-9,624,000 | $59,972,000 | $-44,447,000 | $66,185,000 |
| Cash Flow From Continuing Investing Activities | $-9,624,000 | $59,972,000 | $-44,447,000 | $66,185,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $196,976,000 | $14,221,000 | $119,519,000 | $27,354,000 |
| Financing Cash Flow | $263,305,000 | $54,782,000 | $134,194,000 | $51,784,000 |
| Cash Flow From Continuing Financing Activities | $263,305,000 | $54,782,000 | $134,194,000 | $51,784,000 |
| Net Preferred Stock Issuance | $0 | $0 | $28,099,000 | $0 |
| Preferred Stock Issuance | $0 | $0 | $28,099,000 | $0 |
| Net Common Stock Issuance | $196,976,000 | $14,221,000 | $91,420,000 | $27,354,000 |
| Common Stock Issuance | $196,976,000 | $14,221,000 | $91,420,000 | $27,354,000 |
| Cash Dividends Paid | - | - | - | $0 |
| Repurchase Of Capital Stock | - | - | - | - |
| Net Other Financing Charges | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-42,579,000 | $-150,000 | $-300,000 | $0 |
| Issuance Of Debt | $75,000,000 | $0 | $14,918,000 | $24,148,000 |
| Interest Paid Supplemental Data | $6,364,000 | $3,774,000 | $3,361,000 | $1,536,000 |
| Income Tax Paid Supplemental Data | $185,000 | $0 | $0 | - |
| End Cash Position | $205,231,000 | $89,059,000 | $79,076,000 | $75,789,000 |
| Beginning Cash Position | $89,059,000 | $79,076,000 | $75,789,000 | $21,493,000 |
| Changes In Cash | $116,172,000 | $9,983,000 | $3,287,000 | $54,296,000 |
| Proceeds From Stock Option Exercised | $33,908,000 | $40,711,000 | $57,000 | $282,000 |
| Net Issuance Payments Of Debt | $32,421,000 | $-150,000 | $14,618,000 | $24,148,000 |
| Net Long Term Debt Issuance | $32,421,000 | $-150,000 | $14,618,000 | $24,148,000 |
| Long Term Debt Payments | $-42,579,000 | $-150,000 | $-300,000 | $0 |
| Long Term Debt Issuance | $75,000,000 | $0 | $14,918,000 | $24,148,000 |
| Net Investment Purchase And Sale | $0 | $60,000,000 | $-44,447,000 | $66,185,000 |
| Sale Of Investment | $0 | $60,000,000 | $52,000,000 | $84,000,000 |
| Purchase Of Investment | $0 | $0 | $-96,447,000 | $-17,815,000 |
| Net Intangibles Purchase And Sale | $-9,624,000 | $0 | $0 | - |
| Purchase Of Intangibles | $-9,624,000 | $0 | $0 | - |
| Net PPE Purchase And Sale | $0 | $-28,000 | $0 | $0 |
| Purchase Of PPE | $0 | $-28,000 | $0 | $0 |
| Change In Working Capital | $26,004,000 | $3,718,000 | $-957,000 | $3,900,000 |
| Change In Payables And Accrued Expense | $39,255,000 | $4,841,000 | $5,221,000 | $1,961,000 |
| Change In Accrued Expense | $30,833,000 | $7,999,000 | $2,938,000 | $-638,000 |
| Change In Payable | $8,422,000 | $-3,158,000 | $2,283,000 | $2,599,000 |
| Change In Account Payable | $8,422,000 | $-3,158,000 | $2,283,000 | $2,599,000 |
| Change In Prepaid Assets | $-2,605,000 | $-596,000 | $-5,826,000 | $744,000 |
| Change In Inventory | $-1,833,000 | $0 | $0 | $0 |
| Change In Receivables | $-8,813,000 | $-200,000 | $31,000 | $485,000 |
| Changes In Account Receivables | $-8,813,000 | $0 | $31,000 | $485,000 |
| Other Non Cash Items | $6,508,000 | $-4,369,000 | $-4,058,000 | $74,000 |
| Stock Based Compensation | $9,404,000 | $7,342,000 | $5,860,000 | $6,047,000 |
| Depreciation Amortization Depletion | $728,000 | $26,000 | $62,000 | $118,000 |
| Depreciation And Amortization | $728,000 | $26,000 | $62,000 | $118,000 |
| Amortization Cash Flow | $698,000 | $0 | $0 | $0 |
| Amortization Of Intangibles | $698,000 | $0 | $0 | $0 |
| Depreciation | $30,000 | $26,000 | $62,000 | $118,000 |
| Gain Loss On Investment Securities | $27,492,000 | $19,149,000 | - | - |
| Net Income From Continuing Operations | $-209,471,000 | $-130,637,000 | $-87,367,000 | $-73,812,000 |
| Change In Other Working Capital | - | $-327,000 | $-383,000 | $710,000 |
| Interest Paid Cff | - | - | - | $0 |
| Change In Other Current Liabilities | - | - | - | $0 |
| Change In Other Current Assets | - | - | - | $0 |
| Common Stock Payments | - | - | - | - |
Fetched: 2026-07-16